RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease (CleaR-MAC)
Primary Purpose
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
Status
Active
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
RHB-204
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Pulmonary Mycobacterium Avium Complex Infection focused on measuring MAC, Bronchiectasis, NTM
Eligibility Criteria
Key Inclusion Criteria
- Males and females aged ≥18 years to ≤85 years of age, inclusively
- Have a MAC lung infection documented by one MAC positive culture within 18 months prior to screening and a MAC positive culture at screening (cultures need to be at least 1 month apart). Prior sputum for culture may be obtained from sputum or bronchial washings however, sputum collected during screening must be either spontaneously expectorated by the patient or after sputum induction.
- Have MAC lung infection with evidence of underlying nodular infiltrates and/or bronchiectasis on a chest computed tomography (Chest CT) within 6 months of screening.
- Have symptoms of MAC lung infection that include one of the following: respiratory symptoms such as chronic cough, excessive mucous production, fatigue, dyspnea, hemoptysis or systemic symptoms such as fever, night sweats or loss of appetite.
- Be treatment naïve, or if previously treated for MAC, have not received treatment within the 6 months prior to screening
- Subject's weight is above 41 Kilograms or 90 pounds.
Key Exclusion Criteria
- Cavitary lung disease as observed on a chest CT scan (cavitary lesions exceeding 2 cm in diameter).
- Currently taking or treated in the 6 months prior to screening with any of the following: bedaquiline, clofazimine or any component of American Thoracic Society(ATS)/Infectious Diseases Society of America (IDSA) multi-drug recommended therapy (macrolides, ethambutol, rifabutins/rifampins) for MAC or other multi-drug regime for NTM lung disease
- Clarithromycin minimum inhibitory concentration (MIC) ≥32μg/mL on MAC isolates in screening sputum
- Known hypersensitivity or suspected history of hypersensitivity reactions to clarithromycin, rifabutin, or clofazimine or other drugs in each class
- Subjects requiring chronic supplemental oxygen use (including intermittent or continuous use)
- Planned lung resection surgery for MAC lung disease
- Subjects with Cystic Fibrosis, prior solid organ or hematologic transplant
- Current usage of inhaled products containing amikacin, tobramycin or gentamicin
- History of ventricular arrhythmias or family history of Long QT syndrome, including torsades de pointes
- Corrected QT (QTc) interval on electrocardiogram (ECG) >460 ms for females or >450 ms for males, calculated using Fridericia's formula (QTcF)
Sites / Locations
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility 1
- Medical Facility 2
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
- Medical Facility
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
RHB-204
Placebo
Arm Description
Each capsule contains clarithromycin 158.3mg; rifabutin 40mg; clofazimine 13.3mg.
Matching placebo will contain riboflavin, a type of B vitamin, which may discolor urine in a similar fashion as RHB-204.
Outcomes
Primary Outcome Measures
Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo
The mean change in the Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo
Sputum culture conversion (SCC)
The proportion of subjects who achieve SCC by Month 6, defined by 3 consecutive monthly negative sputum cultures, without reversion, at Months 4, 5 & 6 for THB-204 compared to placebo.
Secondary Outcome Measures
Part 1 Secondary efficacy objective - Reduction of fatigue
The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 6 for RHB-204 compared to placebo. The PROMIS Fatigue SF 8a score from baseline to Month 6 for RHB-204 compared to placebo.
Part 1 Secondary efficacy objective - Time to culture conversion
The time to SCC (month of first negative sputum culture) for RHB-204 compared to placebo.
Part 1 Secondary efficacy objective - Improvement in Physical Functioning
The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 6 for RHB-204 compared to placebo.
Part 2 Secondary efficacy objective - Durable Sputum culture conversion at end of study
The proportion of subjects with SCC by Month 6 who sustain negative sputum cultures at Month 16 and negative sputum culture at Month 19 (3 months off treatment) for RHB-204 compared to placebo (durable responders).
Part 2 Secondary efficacy objective - Durable Sputum culture conversion at end of treatment
Measure the proportion of subjects with SCC by Month 6 who sustain negative sputum cultures at Month 16 for RHB-204 compared to placebo.
QoL B Respiratory Symptoms domain score mean change from baseline to Month 16
The mean change in Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain scores from baseline to Month 16 for ex-RHB-204 compared to ex-placebo
Part 2 Secondary efficacy objective - Improvement in Quality of Life - Fatigue 16 months
The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 16 for ex-RHB-204 compared to ex-placebo
Part 2 Secondary efficacy objective - Improvement in Quality of Life - Fatigue 19 Months
The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 19 for ex-RHB-204 compared to ex-placebo
Part 2 Secondary efficacy objective - Quality of Life Physical Functioning Symptoms 16 Months
The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 16 for ex-RHB-204 compared to ex-placebo
Part 2 Secondary efficacy objective - Quality of Life Physical Functioning Symptoms 19 Months
The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 19 for ex-RHB-204 compared to ex-placebo
QoL-B Respiratory Symptoms domain scores at Month 19
The mean change in Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain scores from baseline to Month 19 for ex-RHB-204 compared to ex-placebo
Full Information
NCT ID
NCT04616924
First Posted
October 19, 2020
Last Updated
June 5, 2023
Sponsor
RedHill Biopharma Limited
1. Study Identification
Unique Protocol Identification Number
NCT04616924
Brief Title
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Acronym
CleaR-MAC
Official Title
Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RedHill Biopharma Limited
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.
Detailed Description
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung infection.
The co-primary efficacy endpoints at the end of Part 1 evaluate the proportion of patients with sputum culture conversion after 6 months of treatment defined as three consecutive monthly negative sputum cultures at Months 4, 5, and 6 for RHB-204 compared to placebo and the mean change in the Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo.
At the Month 6 visit (end of Part 1), after all assessments including questionnaires and sputum samples have been collected, subjects will enter Part 2 of the study and receive open-label RHB-204.
In order to comply with current treatment duration guidelines (Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex: Developing Drugs for Treatment - FDA Draft Guidance September 2021) in this protocol subjects will receive active treatment for 12 months after sputum culture conversion. As such, each subject's first negative culture that defines conversion will determine the total duration of their active study drug treatment. The longest duration of active study drug treatment will be 16 months. At the end of study treatment, all subjects will enter a 3-month post-treatment follow-up period (see study design section below for additional details).
To maintain the blind and integrity of the data, an independent team (Sputum Culture Monitors) will inform sites on each subject's treatment duration based on sputum culture conversion. Sputum Culture Monitors will also have access to randomized treatment allocation. All other study related personnel will remain blinded to sputum culture results and treatment allocation (Sponsor, CRO, medical monitors, safety, ECG and sputum laboratories, site personnel as well as participating subjects).
During Part 1, subjects who have completed at least the first 3 months of treatment with study drug, and at the Investigator's discretion, require rescue therapy (alternative anti-NTM treatment) will discontinue study drug (performing an EOT visit) and remain in the study to complete all scheduled study visits and assessments/procedures to Month 6 (performing an EOS visit).
Subjects who complete treatment based on the timeline provided by the Sputum Culture Monitors (EOT visit) and have an ongoing negative sputum culture will be reconsented to enter a follow-up Extension Study, to evaluate sputum culture results at two (2) further time points: 6 months and 12 months following end of treatment (EOT) for each subject in protocol RHB-204-01.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
Keywords
MAC, Bronchiectasis, NTM
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
125 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
RHB-204
Arm Type
Experimental
Arm Description
Each capsule contains clarithromycin 158.3mg; rifabutin 40mg; clofazimine 13.3mg.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo will contain riboflavin, a type of B vitamin, which may discolor urine in a similar fashion as RHB-204.
Intervention Type
Drug
Intervention Name(s)
RHB-204
Other Intervention Name(s)
Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg
Intervention Description
RHB-204
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo to RHB-204
Primary Outcome Measure Information:
Title
Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo
Description
The mean change in the Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo
Time Frame
6 months
Title
Sputum culture conversion (SCC)
Description
The proportion of subjects who achieve SCC by Month 6, defined by 3 consecutive monthly negative sputum cultures, without reversion, at Months 4, 5 & 6 for THB-204 compared to placebo.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Part 1 Secondary efficacy objective - Reduction of fatigue
Description
The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 6 for RHB-204 compared to placebo. The PROMIS Fatigue SF 8a score from baseline to Month 6 for RHB-204 compared to placebo.
Time Frame
6 months
Title
Part 1 Secondary efficacy objective - Time to culture conversion
Description
The time to SCC (month of first negative sputum culture) for RHB-204 compared to placebo.
Time Frame
6 months
Title
Part 1 Secondary efficacy objective - Improvement in Physical Functioning
Description
The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 6 for RHB-204 compared to placebo.
Time Frame
6 months
Title
Part 2 Secondary efficacy objective - Durable Sputum culture conversion at end of study
Description
The proportion of subjects with SCC by Month 6 who sustain negative sputum cultures at Month 16 and negative sputum culture at Month 19 (3 months off treatment) for RHB-204 compared to placebo (durable responders).
Time Frame
19 months
Title
Part 2 Secondary efficacy objective - Durable Sputum culture conversion at end of treatment
Description
Measure the proportion of subjects with SCC by Month 6 who sustain negative sputum cultures at Month 16 for RHB-204 compared to placebo.
Time Frame
16 months
Title
QoL B Respiratory Symptoms domain score mean change from baseline to Month 16
Description
The mean change in Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain scores from baseline to Month 16 for ex-RHB-204 compared to ex-placebo
Time Frame
16 months
Title
Part 2 Secondary efficacy objective - Improvement in Quality of Life - Fatigue 16 months
Description
The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 16 for ex-RHB-204 compared to ex-placebo
Time Frame
16 months
Title
Part 2 Secondary efficacy objective - Improvement in Quality of Life - Fatigue 19 Months
Description
The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 19 for ex-RHB-204 compared to ex-placebo
Time Frame
19 months
Title
Part 2 Secondary efficacy objective - Quality of Life Physical Functioning Symptoms 16 Months
Description
The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 16 for ex-RHB-204 compared to ex-placebo
Time Frame
16 months
Title
Part 2 Secondary efficacy objective - Quality of Life Physical Functioning Symptoms 19 Months
Description
The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 19 for ex-RHB-204 compared to ex-placebo
Time Frame
19 Months
Title
QoL-B Respiratory Symptoms domain scores at Month 19
Description
The mean change in Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain scores from baseline to Month 19 for ex-RHB-204 compared to ex-placebo
Time Frame
19 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria
Males and females aged ≥18 years to ≤85 years of age, inclusively
Have a MAC lung infection documented by one MAC positive culture within 18 months prior to screening and a MAC positive culture at screening (cultures need to be at least 1 month apart). Prior sputum for culture may be obtained from sputum or bronchial washings however, sputum collected during screening must be either spontaneously expectorated by the patient or after sputum induction.
Have MAC lung infection with evidence of underlying nodular infiltrates and/or bronchiectasis on a chest computed tomography (Chest CT) within 6 months of screening.
Have symptoms of MAC lung infection that include one of the following: respiratory symptoms such as chronic cough, excessive mucous production, fatigue, dyspnea, hemoptysis or systemic symptoms such as fever, night sweats or loss of appetite.
Be treatment naïve, or if previously treated for MAC, have not received treatment within the 6 months prior to screening
Subject's weight is above 41 Kilograms or 90 pounds.
Key Exclusion Criteria
Cavitary lung disease as observed on a chest CT scan (cavitary lesions exceeding 2 cm in diameter).
Currently taking or treated in the 6 months prior to screening with any of the following: bedaquiline, clofazimine or any component of American Thoracic Society(ATS)/Infectious Diseases Society of America (IDSA) multi-drug recommended therapy (macrolides, ethambutol, rifabutins/rifampins) for MAC or other multi-drug regime for NTM lung disease
Clarithromycin minimum inhibitory concentration (MIC) ≥32μg/mL on MAC isolates in screening sputum
Known hypersensitivity or suspected history of hypersensitivity reactions to clarithromycin, rifabutin, or clofazimine or other drugs in each class
Subjects requiring chronic supplemental oxygen use (including intermittent or continuous use)
Planned lung resection surgery for MAC lung disease
Subjects with Cystic Fibrosis, prior solid organ or hematologic transplant
Current usage of inhaled products containing amikacin, tobramycin or gentamicin
History of ventricular arrhythmias or family history of Long QT syndrome, including torsades de pointes
Corrected QT (QTc) interval on electrocardiogram (ECG) >460 ms for females or >450 ms for males, calculated using Fridericia's formula (QTcF)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin L. Winthrop, MD, MPH
Organizational Affiliation
Oregon Health and Science University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
June L Almenoff, MD, PhD
Organizational Affiliation
RedHill Biopharma, Inc.
Official's Role
Study Chair
Facility Information:
Facility Name
Medical Facility
City
Glendale
State/Province
California
ZIP/Postal Code
91205
Country
United States
Facility Name
Medical Facility
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
Medical Facility
City
Farmington
State/Province
Connecticut
ZIP/Postal Code
06030-1225
Country
United States
Facility Name
Medical Facility
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Medical Facility
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33765
Country
United States
Facility Name
Medical Facility
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Facility Name
Medical Facility
City
Margate
State/Province
Florida
ZIP/Postal Code
33063
Country
United States
Facility Name
Medical Facility 1
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Medical Facility 2
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Medical Facility
City
Sebring
State/Province
Florida
ZIP/Postal Code
33870
Country
United States
Facility Name
Medical Facility
City
Vero Beach
State/Province
Florida
ZIP/Postal Code
32960
Country
United States
Facility Name
Medical Facility
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Medical Facility
City
Valdosta
State/Province
Georgia
ZIP/Postal Code
31605
Country
United States
Facility Name
Medical Facility
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Medical Facility
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
Medical Facility
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Medical Facility
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55902
Country
United States
Facility Name
Medical Facility
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Medical Facility
City
Newark
State/Province
New Jersey
ZIP/Postal Code
07103
Country
United States
Facility Name
Medical Facility
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Medical Facility
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Medical Facility
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Medical Facility
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Medical Facility
City
Tyler
State/Province
Texas
ZIP/Postal Code
75708
Country
United States
Facility Name
Medical Facility
City
Wauwatosa
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
We'll reach out to this number within 24 hrs